Experience with New Clotting Products in the Treatment of Hemophilia-Related Bleeding Episodes

  • D. B. Brettler
Conference paper

Abstract

Factor concentrate products have changed significantly over the last decade. Efficacy of concentrates has been very good with adequate hemostasis being achieved utilizing most concentrates. However, two issues have emerged regarding concentrates, their safety, that is freedom from transfusion transmitted viruses, and their purity. Newer products are now available that are both much safer and highly pure.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bell BA, Kurcynski EM, Bergman G. Inhibitors to monoclonal antibody verified factor VIII. Lancet 1990; 335:638CrossRefGoogle Scholar
  2. 2.
    Kessler CM, Sachs K. Factor VIII: C inhibitor associated with monoclonal antibody purified Factor VIII concentrate Lancet 1990; 335:1403PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • D. B. Brettler

There are no affiliations available

Personalised recommendations